First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients
Status:
Completed
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate, for the first time in humans, safety and tolerability of
single ascending doses of intra-articular (i.a.) injections of LRX712 into the knee of
patients with moderate osteoarthritis (OA), in order to support the further clinical
development. This study will also allow establishment of the systemic and local
pharmacokinetics (PK) of LRX712 and the exploration of biomarkers of cartilage breakdown and
regeneration in OA patients.